Evidence map›Paper›PMID 41535351›Full record

ArticleScientific reports2026

Identification and validation of a refined CAF-Associated diagnostic signature in breast cancer.

Xin Zhou, Na Wang, Ling Shi, Dongxin Wei, Xiaoqin Sun, Mingxiu Shao, Liang Tian, Xiaolong Guo, Fangyuan Zhang, Hui Lyu

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin ZhouDepartment of Breast and Thyroid Surgery, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Na WangDepartment of Pathology, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Ling ShiDepartment of Pathology, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Dongxin WeiDepartment of Breast and Thyroid Surgery, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Xiaoqin SunDepartment of Pathology, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Mingxiu ShaoClinical Laboratory, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Liang TianDepartment of Breast and Thyroid Surgery, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Xiaolong GuoDepartment of Breast and Thyroid Surgery, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Fangyuan ZhangDepartment of Breast and Thyroid Surgery, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China.
Hui LyuClinical Laboratory, Zibo Maternal and Child Health Hospital, Zibo, Shandong, China. Lyuhui080806@163.com.

Funding

Zibo City Medical and Health Science Research Projects No. 2023030926
6 · The paper itself

Abstract

Breast cancer remains a major global health challenge with high incidence and mortality rates among women. Recent studies have highlighted the critical role of the tumor microenvironment, particularly cancer-associated fibroblasts (CAFs), in tumor progression. However, current understanding of CAFs heterogeneity and its implications for breast cancer diagnosis and treatment remains limited. This study aimed to identify and validate refined marker genes for CAFs and to develop a diagnostic model to improve breast cancer diagnosis and therapeutic strategies. We employed various machine learning algorithms to identify feature genes associated with CAFs. Based on these genes, we constructed a high-precision diagnostic model for breast cancer. Furthermore, through single-cell analysis, we delved into the heterogeneity of CAFs and predicted the sensitivity of different CAF subsets to specific drugs. To validate the expression of these characteristic genes, immunohistochemical (IHC) experiments were also conducted. This study used machine learning to identify FXYD1, SULF1, and TNXB as refined biomarkers for CAFs in breast cancer. Among these evaluated algorithms, the Random Forest algorithm distinctly stood out as the best due to its robust classification accuracy and stability. Single-cell analysis provided insights into the heterogeneity of CAFs between Luminal and non-Luminal breast cancer, thereby enhancing our understanding of the tumor microenvironment. Drug sensitivity predictions indicated that distinct CAF subsets responded differently to specific drugs, laying a solid foundation for the development of personalized breast cancer treatment strategies. Through IHC, the expression patterns of these three biomarkers were verified: FXYD1 was expressed in myoepithelial and fibroblasts in normal breast tissue but was significantly absent in breast cancer; SULF1 was upregulated in fibroblasts of breast cancer; while the expression of TNXB did not exhibit notable variations between normal and cancerous tissues. These findings not only highlight the crucial roles played by FXYD1, SULF1, and TNXB in the development of breast cancer, but also uncover the heterogeneity CAFs. Consequently, our research provides a fresh perspective and a solid theoretical basis for advancing both early and precise diagnostic methods, as well as tailored therapeutic strategies.

Indexed as

Biomarkers, TumorBreast NeoplasmsCancer-Associated FibroblastsFemaleGene Expression Regulation, NeoplasticHumansMachine LearningSingle-Cell AnalysisSulfotransferasesTumor MicroenvironmentBiomarkers, TumorSulfotransferasesBreast cancerCancer-associated fibroblastsDiagnostic modelImmunohistochemistryMachine learning

Identifiers

PMID41535351
PMCPMC12867992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.